Visionary Holdings Signs Cooperation Agreement with Strategic Investment Partner for Proposed US$20 Million Investment in Qingdao Anti-Aging Project

Rhea-AI Summary

Visionary Holdings (NASDAQ: GV) signed an Investment Cooperation Agreement for a proposed US$20 million strategic investment to advance a Qingdao anti-aging project in Qingdao West Coast New Area, China. The plan calls for a project company, a GV China Anti-Aging Research Center, and a GV Anti-Aging Health Management Center chain.

The investor intends to invest no less than US$20 million in two phases, with an initial milestone-based phase (payments of 30%/40%/30%) and a contemplated second-phase US$10 million. Progress remains subject to definitive agreements, due diligence, regulatory steps, and customary closing conditions.

Positive

• Proposed US$20 million investment in Qingdao project
• Initial milestone funding split: 30% / 40% / 30%
• Contemplated additional US$10 million second phase
• Planned GV China Anti-Aging Research Center and health centers

Negative

• Investment contingent on definitive agreements and due diligence
• Second-phase US$10 million is conditional on development progress
• Profitability and market targets are goals, not guaranteed outcomes

Market Reaction – GV

+21.60% $0.28 21.5x vol

15m delay 38 alerts

+21.60% Since News

+58.6% Peak in 47 min

$0.28 Last Price

$0.20 $0.39 Day Range

+$275K Valuation Impact

$1.55M Market Cap

21.5x Rel. Volume

Following this news, GV has gained 21.60%, reflecting a significant positive market reaction. Argus tracked a peak move of +58.6% during the session. Our momentum scanner has triggered 38 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.28. This price movement has added approximately $275K to the company's valuation. Trading volume is exceptionally heavy at 21.5x the average, suggesting very strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Proposed investment: US$20 million Initial phase funding: US$10 million Second-phase investment: US$10 million +5 more

8 metrics

Proposed investment US$20 million Total strategic investment intended for Qingdao anti-aging project company

Initial phase funding US$10 million First phase of investment into the project company

Second-phase investment US$10 million Contemplated follow-on investment subject to subsequent development progress

Milestone payment 1 30% Paid after project company established and capital account opened

Milestone payment 2 40% Paid after research center renovation and equipment installation

Milestone payment 3 30% Paid after first flagship center opens and first month operating data

Profitability target 1 year Goal to achieve profitability for first anti-aging center after investment completion

Market position goal 2 years Aim to reach leading market position within two years

Market Reality Check

Price: $0.2269 Vol: Volume 58,940,028 vs 20-d...

high vol

$0.2269 Last Close

Volume Volume 58,940,028 vs 20-day average 6,040,495 (about 9.76x typical activity). high

Technical Price 0.2269 is trading below 200-day MA of 1.42, despite the news-driven bounce.

Peers on Argus

GV gained 13.91% while momentum peers showed mixed/negative moves, including KID...

1 Up 3 Down

GV gained 13.91% while momentum peers showed mixed/negative moves, including KIDZ up sharply and EEIQ, GSUN, YQ down (sector scanner median about -4.9%). This pattern points to a GV-specific reaction rather than a broad education-sector move.

Common Catalyst Most peers lacked same-day news; GV’s move appears tied to its anti-aging investment agreement rather than a sector-wide catalyst.

Historical Context

5 past events · Latest: Mar 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 26	China distribution deal	Positive	-6.8%	Strategic cooperation to distribute V-series anti-aging products across ~10,000 stores.
Mar 09	Exclusive agreement & divestiture	Positive	-16.6%	US$12M exclusive distribution plus exit from non-core businesses to refocus on aesthetics.
Mar 05	Growth outlook update	Positive	-2.4%	2026–2027 outlook highlighting RAMU anti-aging line targeting US$30M annual sales.
Mar 02	Exclusive distribution deal	Positive	-5.1%	Exclusive US$12M distribution for regenerative injection and strategic education exit.
Feb 24	Sales contract progress	Positive	-9.3%	Update on execution of approximately US$9M commercial sales agreement in Hong Kong.

Pattern Detected

Over the past five news events, largely positive strategic and commercial updates were followed by negative 24h price reactions, indicating a pattern of selling into good news.

Recent Company History

In the last few months, Visionary announced several healthcare-focused initiatives: a US$9 million sales contract, a strategic exit from non-core education to focus on medical aesthetics with a US$12 million exclusive agreement, and a 2026–2027 outlook targeting US$30 million in potential RAMU anti-aging sales. Most of these strategic and revenue-focused updates saw 24-hour declines between about -2% and -17%, contrasting with today’s positive reaction to another anti-aging expansion announcement.

Market Pulse Summary

The stock is surging +21.6% following this news. A strong positive reaction aligns with the clearly ...

Analysis

The stock is surging +21.6% following this news. A strong positive reaction aligns with the clearly expansionary nature of this Qingdao anti-aging agreement, especially given the contemplated US$20 million project funding and defined milestones. Historically, GV’s stock often fell after upbeat announcements, so a gain of about 13.91% and volume near 10x average pointed to a shift in how investors absorbed its pivot into anti-aging infrastructure, though execution and regulatory milestones remained key swing factors.

Key Terms

cell therapy, biologics, translational development, environmental review, +2 more

6 terms

cell therapy medical

"focus on research and translational development in areas including cell therapy and biologics"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

biologics medical

"focus on research and translational development in areas including cell therapy and biologics"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

translational development medical

"initial focus on research and translational development in areas including cell therapy"

The process of turning early scientific discoveries into practical medical tests, drugs or devices that can be tested in people and sold. Think of it as moving an idea from a prototype in a lab to a product that works reliably in the real world—this involves proving it works in animals or small human studies, scaling up production, and meeting regulatory requirements. Investors care because progress through these steps reduces technical and regulatory risk and creates clear milestones that can increase a program’s value.

environmental review regulatory

"foreign investment filings, environmental review, and healthcare-related qualification approvals"

An environmental review is a formal assessment of how a planned project or business activity could affect air, water, land, wildlife and community health, often required by regulators before permits are granted. Like a home inspection for a building project, it can reveal problems that add cost, require redesign, or delay approval, so investors watch reviews as a sign of regulatory risk, potential extra expense, or timeline shifts.

intellectual property technical

"valuation is expected to be determined with reference to the value of the Company’s contributed intellectual property"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

due diligence financial

"final ownership percentages to be determined in definitive transaction documents following appraisal and due diligence"

Due diligence is the careful investigation and analysis someone conducts before making a decision, such as investing money or entering into an agreement. It’s like researching thoroughly before buying a used car to ensure it’s in good condition; this helps prevent surprises and makes informed choices. For investors, due diligence reduces risk by verifying details and understanding what they’re getting into.

AI-generated analysis. Not financial advice.

Qingdao anti-aging project advances toward staged execution

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) today announced that it has entered into an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. in connection with a proposed US$20 million strategic investment for the Company’s Qingdao anti-aging project in Qingdao West Coast New Area, China.

Under the agreement, the parties plan to establish a project company to serve as the operating entity for the collaboration. The project company is expected to establish the “GV China Anti-Aging Research Center” in Qingdao West Coast New Area, with an initial focus on research and translational development in areas including cell therapy and biologics. In parallel, the project company is also expected to begin building out a “GV Anti-Aging Health Management Center” chain model in China, initially with a focus on the Shandong market and with the goal of introducing internationally aligned products and service standards.

According to the cooperation framework, the investor intends to make a total investment of no less than US$20 million into the project company in two phases. The initial phase is structured around three milestone-based payments: 30% upon establishment of the project company and opening of its capital account, 40% upon completion of renovation of the research center and installation of equipment, and the final 30% after the first flagship center opens and generates its first month of operating data. A second-phase investment of US$10 million is contemplated subject to the Company’s subsequent development progress.

In addition to the proposed investment, the agreement provides for a range of implementation-related support measures, including coordination of local resources in Qingdao West Coast New Area, provision of preferential office and R&D space, talent housing support, assistance with business registration, foreign investment filings, environmental review, and healthcare-related qualification approvals, as well as joint development of a Sino-U.S. international life sciences incubator intended to attract upstream and downstream participants.

The agreement also outlines an initial investment framework for valuation and ownership. Based on the parties’ preliminary understanding, the project company’s pre-investment valuation is expected to be determined with reference to the value of the Company’s contributed intellectual property and cash capital, and, following the initial US$10 million phase of investment, the investor’s equity interest is currently contemplated on a preliminary basis, with final ownership percentages to be determined in definitive transaction documents following appraisal and due diligence.

The project company is also expected to operate with exclusive and lawful technology authorization, with core management and technical personnel to be designated to support ongoing operations. The agreement also references operating and development targets, including the goal of achieving profitability for the first anti-aging center within one year following completion of the investment and the pursuit of a leading market position within two years.

Xiyong Hou, Chief Executive Officer of Visionary, stated:

“We believe this agreement provides a defined framework for the proposed project, including a contemplated project vehicle, a phased funding structure, implementation milestones, regional support measures, and a basis for subsequent definitive documentation. We intend to continue advancing the formal investment agreement and shareholder agreement and move the project toward operational implementation as efficiently as possible. The timing of any initial financing remains subject to the execution of definitive agreements and the satisfaction of customary closing conditions.”

The Company further noted that progress under the proposed cooperation will depend on subsequent definitive agreements, establishment of the project company, capital arrangements, and implementation milestones. Subject to applicable law and disclosure requirements, the Company intends to provide further updates regarding definitive agreements, establishment of the project company, first-phase capital arrangements, construction of the research center, and launch of the first operating site as and when material developments occur.

About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook”, “objective” and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings

FAQ

What is the size and structure of the proposed GV (NASDAQ: GV) investment in Qingdao announced March 31, 2026?

The proposed investment totals at least US$20 million, planned in two phases with milestone payments. According to the company, the initial phase is milestone-based and a second US$10 million tranche is contemplated subject to progress and due diligence.

How are the initial milestone payments for GV's Qingdao project structured?

The initial phase uses three milestone payments of 30%/40%/30% tied to company setup, renovation/equipment, and first-month operating data. According to the company, payments follow establishment, research center completion, and flagship center operating data milestones.

What facilities will GV build in Qingdao under the cooperation agreement?

GV plans a China Anti-Aging Research Center and a GV Anti-Aging Health Management Center chain focused on Shandong. According to the company, the project targets research, translational development, and a chain model with international product and service standards.

When does GV expect the first anti-aging center to become profitable under the plan?

The agreement sets a target of achieving profitability for the first center within one year after investment completion. According to the company, this is an operating target dependent on definitive agreements and milestone achievement.

What conditions could delay GV's Qingdao investment and project launch?

Progress depends on execution of definitive agreements, establishment of the project company, capital arrangements, and regulatory approvals. According to the company, customary closing conditions, due diligence, and government filings could affect timing and implementation.

How will ownership and valuation be determined for the GV Qingdao project company?

Pre-investment valuation will reference contributed intellectual property and cash, with final ownership set after appraisal and due diligence. According to the company, definitive transaction documents will determine final equity percentages following valuation and documentation.